吸入一氧化氮治疗在静脉-动脉体外膜氧合联合Impella支持的CS患者中的影响:回顾性队列研究
该单中心回顾性队列纳入2019年9月至2024年3月连续48例接受ECPELLA支持的心源性休克患者,其中25例接受iNO治疗。iNO组PAPi随时间显著改善,Impella流量呈增加趋势;iNO组VA-ECMO撤机率显著更高(88% vs 48%,P=0.002),撤机时间更短(5[3-6]天 vs 7[6-13]天,P=0.0008),30天生存率显著更高(76% vs 26%,P=0.0002)。作者认为iNO通过改善右心室功能、促进VA-ECMO撤机,与短期预后相关。
要点
- ECPELLA患者中,iNO组VA-ECMO撤机率88% vs 无iNO组48%(P=0.002),撤机时间5[3-6]天 vs 7[6-13]天(P=0.0008)。
- iNO组30天生存率76% vs 无iNO组26%(P=0.0002),Kaplan-Meier分析显示显著差异。
- iNO组PAPi随时间显著改善,Impella流量呈增加趋势。
- 两组基线特征及机械循环支持启动时乳酸水平无显著差异。
- 作者认为iNO通过改善右心室功能、促进VA-ECMO撤机,与短期预后相关。
适用人群与场景
- 2019年9月至2024年3月在本院接受ECPELLA(VA-ECMO联合Impella)支持的连续心源性休克患者,共48例,其中25例接受iNO治疗。
研究设计与关键结果
- 单中心回顾性队列研究,纳入48例ECPELLA患者,iNO组25例,无iNO组23例;两组基线特征及机械循环支持启动时乳酸水平无显著差异。
- iNO组PAPi随时间显著改善,Impella流量呈增加趋势。
- iNO组VA-ECMO撤机率88% vs 无iNO组48%(P=0.002),撤机时间5[3-6]天 vs 7[6-13]天(P=0.0008)。
- iNO组30天生存率76% vs 无iNO组26%(P=0.0002),Kaplan-Meier分析显示显著差异。
证据类型、等级与局限
- 证据类型:单中心回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在需要ECPELLA支持的心源性休克患者中,iNO治疗通过改善右心室功能、促进VA-ECMO撤机,与短期预后相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The mortality rate of patients with cardiogenic shock (CS) requiring veno-arterial extracorporeal membrane oxygenation (VA-ECMO) combined with Impella (ECPELLA) support remains high. Inhaled nitric oxide (iNO) improves right ventricular (RV) function, resulting in increased Impella flow, which may facilitate early withdrawal of VA-ECMO and improve survival. This study investigated the prognostic impact of iNO therapy in ECPELLA patients.
METHODS: We retrospectively analyzed the data of consecutive patients with CS supported by ECPELLA from September 2019 to March 2024 at our hospital. Changes in pulmonary artery pulsatility index (PAPi) and Impella flow over time were evaluated, and VA-ECMO withdrawal rate, time to withdrawal, and 30-day survival were compared between ECPELLA patients with and without iNO therapy.
RESULTS: Of the 48 ECPELLA patients, 25 were treated with iNO. There were no significant differences between the groups in baseline characteristics or lactate levels at mechanical circulatory support induction. Patients with iNO therapy demonstrated significant improvements in the PAPi over time and a trend toward increased Impella flow, as well as a significantly higher VA-ECMO withdrawal rate (88% vs. 48%, P = 0.002) and a shorter time to VA-ECMO withdrawal (5 [3-6] days vs. 7 [6-13] days, P = 0.0008) than those without iNO therapy. Kaplan-Meier analysis demonstrated that the 30-day survival rate was significantly higher in patients with iNO than in those without (76% vs. 26%, P = 0.0002).
CONCLUSIONS: iNO therapy in patients with CS requiring ECPELLA was associated with short-term prognosis by improving RV function and facilitating weaning from VA-ECMO. Trial registration Retrospectively registered in UMIN-CTR (Reference No. R00006352).
参考来源
- Yamada N, Ueno M, Onishi K, et al. Impact of inhaled nitric oxide therapy in patients with cardiogenic shock treated with veno-arterial extracorporeal membrane oxygenation combined with Impella: a retrospective cohort study. J Intensive Care. 2024. PMID: 39558216. doi:10.1186/s40560-024-00761-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。